Cellular Therapy for Autoimmune Disease

Dr. Samik Basu joined Cabaletta in December 2019 and recently became Chief Scientific Officer, previously serving as Vice President of Preclinical Research and Translational Medicine. Before Cabaletta, he was Head of Translational Sciences at Adaptimmune Therapeutics, Plc, leading research on TCR-based adoptive immunotherapies. At Merck Research Laboratories, he co-led preclinical development for Keytruda (pembrolizumab). With over 15 years of industry and academic experience, Dr. Basu has held roles at the NIH, Albert Einstein College of Medicine, and the University of Pennsylvania. He earned his M.D. from Temple University and completed residency in Clinical Pathology. Dr. Basu chairs the Clinical Immunology Committee of the American Association of Immunologists and has authored over 15 peer-reviewed articles.Dr. Jinmin Lee joined Cabaletta in November 2019 and currently serves as the Head of Cellular and Molecular Immunology at Cabaletta, where she leads preclinical research efforts on developing cell therapies for autoimmune diseases. Prior to joining Cabaletta, her research focused on cell therapy for targeted depletion of autoreactive B cells in autoimmune diseases, and fundamental B cell biology including mechanisms of naïve and memory B cell activation. She has over 10 years of industry and academic experience in cellular immunology, cell therapy, and autoimmunity with prior roles at the National Institutes of Health and the University of Pennsylvania. Dr. Lee earned her Ph.D. degree in Immunology from Cornell University, followed by postdoctoral training at the National Institute of Allergy and Infectious Diseases and the University of Pennsylvania.

• 1. How the standard of care for autoimmune diseases has evolved from chronic suppression to that of targeted replacement or suppression2. Autologous Regulatory T-cell (Treg) approaches for autoimmune disease3. Autologous Effector T-cell approaches for autoimmune disease. Part I, Antigen Specific Approaches4. Autologous Effector T-cell approaches for autoimmune disease. Part II, Pan B-cell Depletion Approaches5. Autologous Effector T-cell approaches for autoimmune disease. Part III, Pan Plasma Cell Depletion Approaches6. Myeloid Cellular Approaches for Autoimmune Disease7. Allogeneic Cellular Approaches for Autoimmune Disease8. Viral or Nanoparticle-Based Approaches for Autoimmune Disease9. Unique Clinical Considerations for Cellular Therapies for Autoimmune Disease10. Unique Manufacturing Considerations for Cellular Therapies for Autoimmune Disease11. Global Perspectives. Regulatory, Ethical, and Cultural Dimensions of Cellular Therapies12. Future Directions and Challenges for Cellular Therapies in Autoimmune Disease